Novo Nordisk will discontinue its long-acting insulin treatment Levemir in the U.S. by the end of next year, the company announced Wednesday.
AstraZeneca raised its annual earnings forecast on Thursday, helped by strong demand for its cancer drugs, and moved to boost its pipeline in the booming anti-obesity market with a deal costing up to $2 billion.
Senator Elizabeth Warren, an antitrust hawk, expressed disappointment with the U.S. Federal Trade Commission’s decision to allow pharmaceutical firm Amgen to move forward with its acquisition of Horizon Therapeutics.
Bayer is looking to shake things up with some major company changes after reporting “not acceptable” cash flow for the third quarter on Wednesday.
In the third quarter, Gilead‘s growth in its HIV and oncology businesses was nearly completely offset by declining sales from its COVID-19 drug Veklury (remdesivir) and hepatitis C virus portfolio.
Activist investor Elliott Investment Management has bought more than a $1 billion stake in BioMarin Pharmaceutical, according to an exclusive report from Reuters published Tuesday, citing two unnamed sources familiar with the matter.
In its second-quarter earnings report for fiscal year 2023, Eisai touted a sharp increase in the number of patients being treated with its Alzheimer’s disease therapy Leqembi (lecanemab).
For $80 million upfront and the promise of more than $1.2 billion in milestones, Novartis has bought the global rights to develop an oral HDAC6 inhibitor from Chong Kun Dang Pharmaceutical.
The company said the launch of Leqembi in the United States was progressing as planned and that 10,000 patients were expected to be on the drug by the end of March 2024.
In the third quarter, Vertex Pharmaceuticals reported revenue of $2.48 billion, a 6% increase from the same period in 2022. However, these figures fell short of Wall Street’s consensus estimates.
